ICON is a global provider of outsourced drug development services to biopharma, medical device, government, biosimilar and generic organisations.
We offer a full range of clinical, consulting and commercial services that range from trial design to full study execution, and from clinical to post-market commercialisation.
Our services are supported by in-depth therapeutic and regulatory expertise and market-leading technology and analytics.
Our extensive vaccine trial experience spans across multiple therapeutic indications and all age groups and is supported by our ‘Vaccine Center of Excellence’, a group of therapeutic experts to address the unique requirements of vaccine studies.
With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,300 employees.